Common Stock, par value $0.0001
- Symbol
- NTHI
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 3.03, 5.03, 7.01, 9.01 · 8-K
NTHINASDAQEQUITYCurrent
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On September 18, 2026 (the “Effective Date”), the Company filed an Elimination of Certificate of Designation with the Secretary of State of the State of Delaware to terminate the designation of its Series A Preferred Stock (the “Certificate of Elimination”).…
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
NEONC TECHNOLOGIES HOLDINGS, INC. · 8-K · Filed 2026-09-21
Exhibit 99.1 NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution Cash redemption simplifies the capital structure with no common shares issued in the redemption CALABASAS, Calif., Sept. 17, 2026 - NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that it has redeemed for cash all 6,000 outstanding shares of its Series A Convertible Preferred Stock (the “Series A Preferred Stock”) at their aggregate stated value of $6.0 million. Following the redemption, no shares of Series A Preferred Stock remain outstanding. The redemption was funded with a portion of the net proceeds from the Company’s $15 million registered direct offering announced on September 9, 2026, consistent with the use of proceeds disclosed for that offering. “We made a deliberate decision to redeem the Series A Preferred Stock in cash and eliminate the potential dilution these securities represented for our shareholders,” said Amir F. Heshmatpour, Executive Chairman, President a…
Open exhibit ↗